SEC Form 3 filed by new insider Sharma Mani
$AZN
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 3 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
| |||||||||||||||
1. Name and Address of Reporting Person*
(Street)
(Country) | 2. Date of Event Requiring Statement
(Month/Day/Year) 03/18/2026 | 3. Issuer Name and Ticker or Trading Symbol
ASTRAZENECA PLC [ AZN ] | |||||||||||||||
| 3a. Foreign Trading Symbol
| 5. If Amendment, Date of Original Filed
(Month/Day/Year) | ||||||||||||||||
| 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
| 6. Individual or Joint/Group Filing (Check Applicable Line)
| ||||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Ordinary Shares | 31,153.4659 | D | |
| Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Restricted Stock Units | (1) | (1) | Ordinary Shares | 2,996.308 | (1) | D | |
| Dividend Equivalent Rights | (2) | (2) | Ordinary Shares | 31.297 | (2) | D | |
| Employee Stock Option (right to buy) | 12/01/2028 | 06/01/2029 | Ordinary Shares | 195 | $123.98(3) | D | |
| Explanation of Responses: |
| 1. Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. The RSUs vest on November 16, 2028. Vested ordinary shares will be delivered to the reporting person on November 17, 2028. |
| 2. Dividend equivalent rights accrue on the reporting person's RSUs when and as dividends are paid on the Issuer's ordinary shares and vest along with the RSUs on which they accrued. Each dividend equivalent right converts into one ordinary share of the Issuer on the date of vesting. |
| 3. The exercise price for these options under the Issuer's Savings Related Share Option Scheme is denominated in British pounds sterling at a price of GBP93.64 per ordinary share. The exercise price reported herein was converted from British pounds sterling to United States dollars at a conversion rate of GBP1.0000 to $1.3240 on March 13, 2026 as published by the Board of Governors of the Federal Reserve System. The exercise price is the actual British pounds sterling amount regardless of the exchange rate on the date of exercise. |
| Remarks: |
| SVP, Group Controller and Head of Global Finance Services |
| /s/ Mani Sharma | 03/19/2026 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
| * Form 3: SEC 1473 (03-26) | ||